Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector; Legislation related to drug supply chain management; Education related to differences between group purchasing organizations and pharmacy benefit managers; Legislation related to drug shortages; S.1339 - Pharmacy Benefit Manager Reform Act; Pandemic and All Hazards Preparedness Act reauthorization.
Duration: October 15, 2021
to
present
General Issues: Health Issues , Medicare/Medicaid , Trade (Domestic & Foreign) , Manufacturing
Spending: about $440,403 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2021: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Robert Van Heuvelen Chief of Staff to Senator Kent Conrad; Director of Office Civil Enforcement, U.S. EnvironmentalProtection Agency; Assistant Counsel, Environmentand Public Works Committee, U.S. Senate
Chief of Staff to Sen. Kent Conrad (D-ND)
Alex Vogel Former Chief Counsel, Senate Majority Leader Bill Frist
Brad Howard Chief of Staff, Rep. Stephanie Murphy
Former Chief of Staff, Rep. Stephanie Murphy
Margaret Gilley Executive Assistant, Legislative Assistant, and Senior Policy Advisor, Rep. Jack Kingston
Bobby Cunningham n/a
Alexander Blair n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, THE VOGEL GROUP lobbied for Healthcare Supply Chain Association , earning $45,600. The report was filed on April 18.
Original Filing: 301554442.xml
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector; Legislation related to drug supply chain management; Education related to differences between group purchasing organizations and pharmacy benefit managers; Legislation related to drug shortages; S.1339 - Pharmacy Benefit Manager Reform Act; Pandemic and All Hazards Preparedness Act reauthorization.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
4th Quarter, 2023
In Q4, THE VOGEL GROUP lobbied for Healthcare Supply Chain Association , earning $44,100. The report was filed on Jan. 19.
Original Filing: 301531132.xml
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector; Legislation related to drug supply chain management, Education related to differences between group purchasing organizations and pharmacy benefit managers; Legislation related to drug shortages; S.1339 - Pharmacy Benefit Manager Reform Act; Pandemic and All Hazards Preparedness Act reauthorization.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
3rd Quarter, 2023
In Q3, THE VOGEL GROUP lobbied for Healthcare Supply Chain Association , earning $44,100. The report was filed on Oct. 18, 2023.
Original Filing: 301504307.xml
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector; Legislation related to drug supply chain management, Education related to differences between group purchasing organizations and pharmacy benefit managers; Legislation related to drug shortages; S.1339 - Pharmacy Benefit Manager Reform Act; Pandemic and All Hazards Preparedness Act reauthorization.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
2nd Quarter, 2023
In Q2, THE VOGEL GROUP lobbied for Healthcare Supply Chain Association , earning $44,100. The report was filed on July 19, 2023.
Original Filing: 301481502.xml
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector; Legislation related to drug supply chain management, Education related to differences between group purchasing organizations and pharmacy benefit managers; Legislation related to drug shortages; S.1339 - Pharmacy Benefit Manager Reform Act; Pandemic and All Hazards Preparedness Act reauthorization.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
1st Quarter, 2023
In Q1, THE VOGEL GROUP lobbied for Healthcare Supply Chain Association , earning $44,100. The report was filed on April 20, 2023.
Original Filing: 301468007.xml
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2022
In Q4, THE VOGEL GROUP lobbied for Healthcare Supply Chain Association , earning $44,100. The report was filed on Jan. 20, 2023.
Original Filing: 301443708.xml
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector; S.3799 - PREVENT Pandemics Act; H.R.6000 - Cures 2.0 Act; H.R. 7667 - The Food and Drug Amendments of 2022; S.4348 - FDASLA Act of 2022; The Affordable Insulin Now Act; drug pricing reform in budget reconciliation legislation
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector; H.R. 2471, the Consolidated Appropriations Act, 2022, specifically the PREVENT Pandemics Act
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector; H.R. 2471, the Consolidated Appropriations Act, 2022, specifically the PREVENT Pandemics Act
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2022
In Q3, THE VOGEL GROUP lobbied for Healthcare Supply Chain Association , earning $44,100. The report was filed on Oct. 20, 2022.
Original Filing: 301419741.xml
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector; S.3799 - PREVENT Pandemics Act; H.R.6000 - Cures 2.0 Act; H.R. 7667 - The Food and Drug Amendments of 2022; S.4348 - FDASLA Act of 2022; The Affordable Insulin Now Act; drug pricing reform in budget reconciliation legislation
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
2nd Quarter, 2022
In Q2, THE VOGEL GROUP lobbied for Healthcare Supply Chain Association , earning $44,100. The report was filed on July 20, 2022.
Original Filing: 301396407.xml
Lobbying Issues
Issues pertaining to group purchasing organizations, including matters related to supply chains in healthcare, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; Issued related to sustainability in the healthcare sector; S.3799 - PREVENT Pandemics Act; H.R.6000 - Cures 2.0 Act; H.R. 7667 - The Food and Drug Amendments of 2022; S.4348 - FDASLA Act of 2022; The Affordable Insulin Now Act; drug pricing reform in budget reconciliation legislation
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
1st Quarter, 2022
In Q1, THE VOGEL GROUP lobbied for Healthcare Supply Chain Association , earning $44,100. The report was filed on April 20, 2022.
Original Filing: 301372107.xml
Lobbying Issues
Health issues specifically related to group purchasing organizations, including matters related to supply chains in health care, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE, and the Strategic National Stockpile; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; ; Executive Orders on the healthcare supply chain; S.3799 - PREVENT Pandemics Act
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
4th Quarter, 2021
In Q4, THE VOGEL GROUP lobbied for Healthcare Supply Chain Association , earning $42,003. The report was filed on Jan. 20, 2022.
Original Filing: 301338799.xml
Lobbying Issues
Health issues specifically related to group purchasing organizations, including matters related to supply chains in health care, including the Strategic National Stockpile, drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act; H.R.5376 - Build Back Better Act; FY2022 Budget Reconciliation; Executive Orders on the healthcare supply chain.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
4th Quarter, 2021
THE VOGEL GROUP filed a lobbying registration on Nov. 22, 2021 to represent Healthcare Supply Chain Association, effective Oct. 15, 2021.
Original Filing: 301318445.xml
Issue(s) they said they’d lobby about: Health issues specifically related to group purchasing organizations, including matters related to supply chains in health care, including drugs and medical devices, drug pricing, and drug shortages; Issues related to incentivizing domestic manufacturing of critical healthcare supplies, including PPE; Pandemic preparedness and response. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...